Rite Aid vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
US pharmacy chain that emerged from Chapter 11 bankruptcy (filed October 2023) following $1.3B+ opioid settlements; competing with CVS and Walgreens with a restructured reduced store network.
About
Rite Aid is a US pharmacy retail chain — historically one of the three largest US drugstore networks alongside CVS and Walgreens — operating neighborhood pharmacies providing prescription medications, immunizations, health screenings, and personal care retail. Founded in 1962 in Scranton, Pennsylvania and headquartered in Camp Hill, Pennsylvania, Rite Aid filed for Chapter 11 bankruptcy protection in October 2023 under the combined pressure of opioid litigation settlements exceeding $1.3 billion, real estate liabilities from 2,200+ store leases, declining pharmacy reimbursement rates from PBMs, and debt from the 2007 acquisition of Eckerd pharmacies. Rite Aid emerged from bankruptcy in 2024 with a restructured balance sheet and reduced store network, closing hundreds of locations while maintaining operations in core markets.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.